Desmoid Tumors Market to Reach US$3.05 Billion by 2033, Growing at a 5.6% CAGR | Key Players: SpringWorks Therapeutics, Immunome & Merck

The global desmoid tumors market size reached US$1.88Billion in 2024 from US$1.79Billion in 2023 and is expected to reach US$ 3.05Billion by 2033, growing at a CAGR of 5.6% from 2025 to 2033., according to DataM Intelligence.

United States: Recent Industry Developments
✅ In October 2025, SpringWorks Therapeutics (a Merck unit) announced publication of long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat) in the Journal of Clinical Oncology, showing further tumor size reductions, increased objective response rates, sustained symptom improvements, and consistent safety with up to 4 years of continuous treatment.
✅ Ongoing real-world adoption of OGSIVEO (nirogacestat) as the first and only FDA-approved targeted therapy (approved November 2023) for adults with progressing desmoid tumors, establishing it as the systemic standard of care.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):
https://www.datamintelligence.com/download-sample/desmoid-tumors-market?sindhuri

Japan: Recent Industry Developments
Japan-focused developments in 2025; however, expanding clinical trial sites in Asia-Pacific (including Japan) by multinational firms like SpringWorks Therapeutics and Immunome to support studies of γ-secretase inhibitors such as nirogacestat and AL102, amid growing rare disease awareness.

Asia-Pacific: Recent Industry Developments
✅ Exponential growth in diagnostic capabilities and access to advanced oncology care; several multinational firms, including SpringWorks Therapeutics and Immunome, expanding clinical trial sites in the region for γ-secretase inhibitors and Wnt/β-catenin pathway agents.
✅ Increasing government support for orphan diseases and inclusion in national healthcare policies in countries like China, India, Japan, and South Korea.

Mergers & Acquisitions
✅ February 2024 - Global: Immunome, Inc. entered into a definitive asset purchase agreement with Ayala Pharmaceuticals, Inc., to acquire AL102 and related candidate AL101 for $20 million cash, $30 million in Immunome common stock, and up to $37.5 million in milestones (transaction supports pipeline advancement in desmoid tumors).

Technological Partnerships
Ongoing academic-industry collaborations and patient registries facilitating trial recruitment; focus on Wnt/β-catenin and Notch pathway inhibitors through partnerships among biotech firms.

New Product/Service Launch
✅ Emphasis on targeted therapies: OGSIVEO (nirogacestat, SpringWorks Therapeutics/Merck) as the first approved gamma secretase inhibitor; pipeline candidates like AL102 (Immunome, Phase 3), tegavivint (Iterion Therapeutics), FOG-001 (Parabilis Medicines), and CB-103 (Cellestia Biotech).
✅ In October 2025, Parabilis Medicines presented first clinical data at ESMO Congress 2025 for investigational FOG-001, demonstrating successful targeting of the β-catenin:TCF complex in Phase 1/2 trial (12 desmoid tumor patients dosed across dose levels as of mid-August 2025).

Technological Advancements in the Market
✅ 2025 trends: Validation of Notch/γ-secretase inhibition pathway via nirogacestat; emerging therapies targeting Wnt/β-catenin pathway; shift toward precision medicine, molecular diagnostics, and targeted agents over traditional surgery/chemotherapy for better efficacy and reduced invasiveness.

Funding Raised by Companies
Recent funding rounds detailed; growth driven by R&D investments, strategic acquisitions (e.g., Immunome-Ayala), and commercial progress of approved therapies like OGSIVEO.

Market Dynamics & Key Insights
✅ Drivers: Expanding clinical pipeline, scientific understanding of Wnt/β-catenin and Notch pathways, FDA (2023) and EC (August 2025) approvals of nirogacestat (OGSIVEO), rising awareness, improved diagnostics, patient advocacy, and R&D investments.
✅ Restraints: Limited approved therapies (OGSIVEO as the only branded option), high costs, access/reimbursement challenges, and reliance on off-label agents (sorafenib, imatinib, pazopanib) with variable efficacy.
✅ Trends: Orphan-drug pricing potential, precision medicine shift, and commercial opportunity from high per-patient costs.
✅ North America dominates; Asia-Pacific fastest-growing with infrastructure improvements and clinical research expansion.

Speak to Our Analyst and Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/desmoid-tumors-market?sindhuri

Segmentation
☛ By Tumor Type
Abdominal Wall Desmoid Tumors, Intra-Abdominal Desmoid Tumors, Extra-Abdominal Desmoid Tumors.
☛ By Treatment Type
Targeted Therapy (dominant with 51.12% revenue share in 2024 and fastest-growing, led by nirogacestat/OGSIVEO and pipeline agents); Radiation Therapy; Chemotherapy; Hormone Therapy; Cryoablation; Others.
☛ By End User
Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Others.

Regional Analysis
» North America leads the global desmoid tumors market with the largest revenue share of 44.17% in 2024; driven by major players (e.g., SpringWorks Therapeutics/Merck), strong regulatory support (FDA approval of OGSIVEO), high awareness, patient advocacy, and robust R&D in the U.S.
» Asia-Pacific exhibits the fastest growth at a CAGR of 5.7% over the forecast period, supported by healthcare infrastructure improvements, rising awareness, expanding clinical trials, and orphan disease policies in China, India, Japan, and South Korea.
» Europe shows strong demand fueled by the European Commission approval of OGSIVEO (nirogacestat) in August 2025 as the first therapy for desmoid tumors in the EU, enabling broader systemic uptake.
» The Middle East and Africa, along with South America, hold emerging potential with increasing access to innovative therapies.

Buy now and enjoy a limited-time discount - limited-time offer!
https://www.datamintelligence.com/buy-now-page?report=desmoid-tumors-market?sindhuri
(Purchase 2 or more Reports and get higher discounts)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription
✅ Competitive Landscape
✅ Technology Innovation Tracker
✅ Export vs. Domestic Consumption Analysis
✅ Healthcare Expert Insights
✅ Digital Transformation & ROI Benchmarks
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us:
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us:
DataM Intelligence is a full-service market research and consulting firm, guiding organizations from initial insight to strategic implementation. We transform proprietary data, emerging trends, and market developments into agile, actionable solutions.
Our robust methodology powers a vast research database featuring 6,300+ syndicated and custom reports across 40+ industries. We have delivered strategic solutions to 200+ companies in 50+ countries, addressing the core research challenges that drive growth for our clients.

This release was published on openPR.